A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

Inclusion Criteria:

* Patients participate in the study voluntarily and sign informed consent；
* Male or female, aged 18 to 75 years (including boundary value);
* Subjects with advanced tumor confirmed by histology or cytology fail to receive standard treatment, or there is no standard treatment scheme, or standard treatment is not applicable at this stage;
* Having adequate organ function；
* ECOG score is 0-1；
* Expected survival ≥ 12 weeks；
* There is at least one assessable tumor focus.

Exclusion Criteria:

* History of severe allergic;
* Those who have received anti-TIGIT or anti-PVRIG therapy in the past;
* Patients who have grade ≥3 immune-mediated adverse event that associated with a prior immunotherapy;
* Adverse reactions to previous antitumor therapy have not recovered to NCI-CTCAE V5.0 rating ≤ 1;
* Current definite interstitial lung disease or non-infectious pneumonitis, except for local radiotherapy;
* Patients ever received the following treatments or drugs prior to the study treatment:

  1. Major organ surgery within 28 days prior to initiation of trial treatment;
  2. Received live attenuated vaccine within 28 days prior to the study treatment;
  3. Received antitumor therapy within 4 weeks prior to the study treatment;
  4. Received systemic glucocorticoid within 14 days prior to the study treatment;
* Active infection was present within 14 days before starting study treatment;
* Those with known uncontrolled parenchymal or leptomeningeal metastases;
* Patients with active autoimmune disease or a history of autoimmune disease with potential for relapse;
* Patients with other active malignancies within 5 years prior to initiation of study treatment, except for locally treatable and cured malignancies;
* History of severe cardiovascular and cerebrovascular diseases;
* Patients with uncontrolled tumor-related pain;
* Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
* History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;
* History of alcohol, psychotropic substance or drug abuse;
* History of psychiatric disorders or poor compliance;
* History of immunodeficiency, including a positive HIV antibody test;
* Patients with active syphilis infection;
* Patients with active hepatitis B or C;
* Pregnant or lactating women;
* Other conditions considered unsuitable for this study by investigator.